TP53 and melanoma: Su et al. found that the expression of PLK1 and NOTCH was associated with poor overall and disease-free survival in melanoma, and the combination of BI6727 with the NOTCH inhibitor MK0752 resulted in a synergistic antiproliferative response in BRAF mutated, BRAF and TP53 mutated, and NRAS mutated melanoma cells (170).